Phase 3 N=500 High-dose Erythropoietin for Asphyxia and Encephalopathy
Neonatal Encephalopathy · Birth Asphyxia
Primary: Number of Participants With Death or Neurodevelopmental Impairment — 126; 110 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Mild Encephalopathy in the Newborn Treated With Darbepoetin
Neonatal Encephalopathy · Hypoxic-Ischemic Encephalopathy Mild
Primary: Normal Neurodevelopment — 13; 14 Participants
Phase 2 N=50 MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
Hepatic Cirrhosis · Hepatic Encephalopathy (HE)
Primary: Ammonia Plasma Levels at Baseline and Day 5 — 70.4; 91.4; 92.6; 78.1 μmol/L
Phase 2 N=18 VE303 for Treatment of Hepatic Encephalopathy (HE)
Cirrhosis · Hepatic Encephalopathy
Primary: Number of Participants Who Experienced Serious Adverse Events up to Week 6 — 2; 0 Participants
N/A N=63 Prospective Research in Infants With Mild Encephalopathy
Hypoxic-Ischemic Encephalopathy · Brain Injury · Neonatal Seizure
Primary: Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality. — 28 Participants
N/A N=17 The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.
Cirrhosis · Ascites · Liver Diseases
Primary: Overall Participant Retention Rate Based on Proportion of Participants Who Complete All Study Visits — 10 Participants
Phase 2 N=15 A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Cirrhosis · Hepatic Encephalopathy
Primary: Part A: The Rate of AEs and Tolerability of HPN-100 — 11; 9; 7; 4 Subjects
N/A N=20 EEG Cap for Identification of Non-Convulsive Status Epilepticus
Nonconvulsive Status Epilepticus · Subclinical Seizure · Altered Mental Status
Primary: Time Difference Between EEG Cap and Standard EEG Results Reporting — 103.4 minutes — p=0.0005
Phase 2 N=50 Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
Hypoxic-ischemic Encephalopathy · Neonatal Encephalopathy · Birth Asphyxia
Primary: Markers of Organ Function — 10; 6; 9; 12 participants
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
N/A N=81 PatiEnt Neuropsychological outcomeS After laseR Ablation
Cognitive Change
Primary: Site-determined Cognitive Changes Per Domain — 49; 50.7; 32.9; 35.3 Score
Phase 2 N=231 Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Acute Episode of Overt Hepatic Encephalopathy · Hepatic Encephalopathy
Primary: Percentage of Participants in Each HE Stage — 11; 6; 30; 40 percentage of participants
N/A N=15 Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy
Hepatic Encephalopathy
Primary: Percentage of Slow Wave Sleep and REM Sleep — 56 percentage of total sleep time per 24h
Phase 3 N=322 Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
Hepatic Encephalopathy
Primary: Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event — 78; 15; 158; 49 Participants
N/A N=50 A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
Hepatic Encephalopathy
Primary: Complete Reversal — 80 percentage of participants
Phase 2 N=18 Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
Developmental and/or Epileptic Encephalopathies
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the…
Phase 2 N=62 Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
Congenital Heart Disease · Hypoplastic Left Heart Syndrome · Transposition of the Great Arteries
Primary: Relative Difference in Total Maturity Score (TMS) From Preoperative Brain MRI to 7 Day Postoperative MRI — 12.1; 9.44 Percentage
N/A N=24 Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy
CTE · TBI (Traumatic Brain Injury)
Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02
Phase 2 N=36 PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
Hyperammonemia
Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 6; 6; 7; 8 participants
Phase 2 N=7 Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
Seizure · Epilepsy · Cerebral Malaria
Primary: Freedom From Seizure — 7 individuals